AU2016222928B2 - PD-1 / PD-L1 inhibitors for the treatment of cancer - Google Patents

PD-1 / PD-L1 inhibitors for the treatment of cancer Download PDF

Info

Publication number
AU2016222928B2
AU2016222928B2 AU2016222928A AU2016222928A AU2016222928B2 AU 2016222928 B2 AU2016222928 B2 AU 2016222928B2 AU 2016222928 A AU2016222928 A AU 2016222928A AU 2016222928 A AU2016222928 A AU 2016222928A AU 2016222928 B2 AU2016222928 B2 AU 2016222928B2
Authority
AU
Australia
Prior art keywords
antibody
cancer
patients
avelumab
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016222928A
Other languages
English (en)
Other versions
AU2016222928A1 (en
Inventor
Jean-Marie CUILLEROT
Anja von HEYDEBRECK
Guojun YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Merck Patent GmbH
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Merck Patent GmbH, Pfizer Inc filed Critical Pfizer Corp Belgium
Publication of AU2016222928A1 publication Critical patent/AU2016222928A1/en
Application granted granted Critical
Publication of AU2016222928B2 publication Critical patent/AU2016222928B2/en
Priority to AU2021204211A priority Critical patent/AU2021204211A1/en
Priority to AU2021204217A priority patent/AU2021204217A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016222928A 2015-02-26 2016-02-23 PD-1 / PD-L1 inhibitors for the treatment of cancer Ceased AU2016222928B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021204211A AU2021204211A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer
AU2021204217A AU2021204217A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562121025P 2015-02-26 2015-02-26
US62/121,025 2015-02-26
US201562133721P 2015-03-16 2015-03-16
US62/133,721 2015-03-16
US201562160291P 2015-05-12 2015-05-12
US62/160,291 2015-05-12
US201562215394P 2015-09-08 2015-09-08
US62/215,394 2015-09-08
US201562254424P 2015-11-12 2015-11-12
US62/254,424 2015-11-12
PCT/US2016/019120 WO2016137985A1 (en) 2015-02-26 2016-02-23 Pd-1 / pd-l1 inhibitors for the treatment of cancer

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2021204211A Division AU2021204211A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer
AU2021204217A Division AU2021204217A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2016222928A1 AU2016222928A1 (en) 2017-10-12
AU2016222928B2 true AU2016222928B2 (en) 2021-05-13

Family

ID=55588542

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016222928A Ceased AU2016222928B2 (en) 2015-02-26 2016-02-23 PD-1 / PD-L1 inhibitors for the treatment of cancer
AU2021204211A Abandoned AU2021204211A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer
AU2021204217A Abandoned AU2021204217A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021204211A Abandoned AU2021204211A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer
AU2021204217A Abandoned AU2021204217A1 (en) 2015-02-26 2021-06-22 PD-1 / PD-L1 inhibitors for the treatment of cancer

Country Status (15)

Country Link
US (2) US10800846B2 (enExample)
EP (2) EP3262073A1 (enExample)
JP (3) JP6885869B2 (enExample)
KR (1) KR20170132171A (enExample)
CN (2) CN112263677A (enExample)
AU (3) AU2016222928B2 (enExample)
BR (1) BR112017018234A2 (enExample)
CA (1) CA2977767C (enExample)
IL (2) IL278423B2 (enExample)
MX (2) MX393976B (enExample)
NZ (1) NZ733854A (enExample)
RU (1) RU2714233C2 (enExample)
SG (2) SG10201810615VA (enExample)
TW (2) TWI748942B (enExample)
WO (1) WO2016137985A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763741A1 (en) 2011-11-28 2021-01-13 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US10800846B2 (en) 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
RU2020124273A (ru) 2015-08-11 2020-12-03 Уси Байолоджикс (Кайман) Инк. Новые анти-pd-1 антитела
KR102434314B1 (ko) 2015-09-01 2022-08-19 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
AU2016368099C1 (en) 2015-12-07 2023-10-12 Merck Patent Gmbh Aqueous Pharmaceutical Formulation Comprising anti-PD-L1 Antibody Avelumab
CA3025391A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
KR102543015B1 (ko) 2016-06-17 2023-06-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법
CN109952316A (zh) * 2016-09-14 2019-06-28 北京韩美药品有限公司 一种能够特异性地结合pd-1的抗体及其功能片段
IL265762B2 (en) * 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018106864A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
AU2018221822A1 (en) * 2017-02-16 2019-09-26 Medimmune, Llc Anti-PD-L1 antibody treatment of bladder cancer
UA129583C2 (uk) 2017-03-06 2025-06-11 Мерк Патент Гмбх Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб
EP3372615A1 (en) 2017-03-06 2018-09-12 Merck Patent GmbH Composition comprising avelumab
KR102644408B1 (ko) * 2017-03-30 2024-03-07 메르크 파텐트 게엠베하 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
KR20200071097A (ko) * 2017-10-13 2020-06-18 메르크 파텐트 게엠베하 Parp 억제제 및 pd-1 축 결합 길항제의 조합
WO2019118855A1 (en) * 2017-12-14 2019-06-20 The Trustees Of The University Of Pennsylvania Compounds and compositions for prevention and/or treatment of cancer
AU2019226011B2 (en) 2018-02-21 2025-11-27 Five Prime Therapeutics, Inc. B7-H4 antibody formulations
JP7430924B2 (ja) * 2018-03-22 2024-02-14 ケイレス アーゲー 拮抗的抗原結合タンパク質
JP2021527083A (ja) * 2018-06-13 2021-10-11 メルク パテント ゲーエムベーハー ステージｉｉｉ ｎｓｃｌｃの治療及びその治療に伴う病理学的状態の鎮静
MX2021003263A (es) * 2018-09-26 2021-05-12 Merck Patent Gmbh Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
MX2021004226A (es) * 2018-10-15 2021-07-15 Five Prime Therapeutics Inc Terapia combinada contra el cáncer.
JP7621943B2 (ja) * 2018-11-14 2025-01-27 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ がんを治療するための、抗ｃｅａｃａｍ６および抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体のいずれかの医薬組み合わせ
US11851490B2 (en) 2019-08-15 2023-12-26 Northwestern University Methods and compositions for treating, inhibiting, and/or preventing heterotopic ossification
US20210169979A1 (en) * 2019-12-05 2021-06-10 The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges System and method for sonosensitized cancer immunotherapy with nanoparticles
CN115151258A (zh) * 2020-01-02 2022-10-04 默沙东有限责任公司 使用pd-1拮抗剂、ilt4拮抗剂和乐伐替尼或盐的组合癌症治疗
AU2020466790B2 (en) * 2020-09-04 2025-07-10 Pharma Mar, S.A. Combination of lurbinectedin and immune checkpoint inhibitor
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
TW202404634A (zh) * 2022-04-05 2024-02-01 美商安進公司 胃癌的治療
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341917A1 (en) * 2011-11-28 2014-11-20 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000475A (en) 1908-12-31 1911-08-15 Rodney Robert Woodson Coal-mining pick.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
JPH07263576A (ja) 1994-03-25 1995-10-13 Hitachi Ltd 半導体集積回路装置およびその製造方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7794710B2 (en) * 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP1613320A1 (en) 2003-04-03 2006-01-11 Pfizer Inc. Dosage forms comprising ag013736
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
BRPI0506726B8 (pt) 2004-01-07 2021-05-25 Chiron Corp anticorpo monoclonal específico para m-csf e usos deste
CN101094836A (zh) 2004-11-02 2007-12-26 辉瑞大药厂 制备吲唑化合物的方法
KR20070058690A (ko) 2004-11-02 2007-06-08 화이자 인코포레이티드 인다졸 화합물의 제조방법
RU2007116150A (ru) 2004-11-02 2008-11-10 Пфайзер Инк. (US) Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола
WO2006048745A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Methods for preparing indazole compounds
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006123223A1 (en) 2005-05-19 2006-11-23 Pfizer Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
WO2008122858A2 (en) 2007-04-05 2008-10-16 Pfizer Products Inc. Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
SI2170959T1 (sl) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Protitelesa proti receptorjem pd-1 za humano programirano smrt
US7960515B2 (en) 2007-12-14 2011-06-14 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010027423A2 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
FI4209510T3 (fi) 2008-12-09 2024-03-22 Hoffmann La Roche Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
US20120089541A1 (en) 2010-08-31 2012-04-12 Genentech, Inc. Biomarkers and methods of treatment
PH12013500395B1 (en) 2010-09-09 2020-10-16 Pfizer 4-1bb binding molecules
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
TW202114735A (zh) 2011-08-01 2021-04-16 美商建南德克公司 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法
AU2012299421B2 (en) 2011-08-23 2016-02-04 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
TW201328725A (zh) 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物
RU2014116407A (ru) 2011-11-11 2015-12-20 Пфайзер Инк. N-метил-2-[3-((e)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]-бензамид для лечения хронического миелоидного лейкоза
WO2013119202A1 (en) 2012-02-06 2013-08-15 Providence Health & Services - Oregon Cancer treatment and monitoring methods using ox40 agonists
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
KR102418979B1 (ko) * 2012-05-15 2022-07-11 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
WO2013181452A1 (en) 2012-05-31 2013-12-05 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
DK2904011T3 (en) * 2012-10-02 2017-12-04 Bristol Myers Squibb Co COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATMENT OF CANCER
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
KR20220053691A (ko) 2013-03-15 2022-04-29 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
EP2981281B1 (en) 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2907973A1 (en) 2013-04-12 2014-10-16 Morphosys Ag Antibodies targeting m-csf
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
MX370818B (es) 2013-09-11 2020-01-08 Medimmune Ltd Anticuerpos anti-b7-h1 para tratar tumores.
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
EP3065772B1 (en) * 2013-11-05 2024-07-24 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015069266A1 (en) 2013-11-07 2015-05-14 Flynn Daniel L Methods for inhibiting tie2 kinase useful in the treatment of cancer
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
US20160303231A1 (en) 2013-12-11 2016-10-20 Robert Iannone Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor
CN105934253A (zh) 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
KR20160099092A (ko) 2013-12-17 2016-08-19 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US9045545B1 (en) * 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
DK3102605T3 (en) 2014-02-04 2019-02-25 Pfizer COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATMENT OF CANCER
WO2015126903A1 (en) 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
CN106255510A (zh) 2014-03-05 2016-12-21 百时美施贵宝公司 使用抗pd‑1抗体与另一抗癌剂的组合治疗肾癌
RU2695332C2 (ru) 2014-05-15 2019-07-23 Бристол-Маерс Сквибб Компани Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
CA2954868C (en) * 2014-07-11 2023-08-29 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
AU2015314756A1 (en) 2014-09-13 2017-03-16 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
WO2016069727A1 (en) * 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN106999583A (zh) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
WO2016089873A1 (en) 2014-12-02 2016-06-09 Celgene Corporation Combination therapies
GB201421647D0 (en) 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US10800846B2 (en) 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
US20180282415A1 (en) 2015-09-30 2018-10-04 Merck Patent Gmbh Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3025391A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
IL265762B2 (en) 2016-10-06 2024-04-01 Merck Patent Gmbh Dosing regimen of avelumab for the treatment of cancer
KR102644408B1 (ko) * 2017-03-30 2024-03-07 메르크 파텐트 게엠베하 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341917A1 (en) * 2011-11-28 2014-11-20 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof

Also Published As

Publication number Publication date
CA2977767A1 (en) 2016-09-01
MX2022001757A (es) 2022-03-11
AU2016222928A1 (en) 2017-10-12
NZ733854A (en) 2022-07-01
JP2018508512A (ja) 2018-03-29
IL278423B2 (en) 2024-04-01
SG11201706918YA (en) 2017-09-28
US20180244781A1 (en) 2018-08-30
JP2021178822A (ja) 2021-11-18
IL254131A0 (en) 2017-10-31
CN112263677A (zh) 2021-01-26
JP2020114840A (ja) 2020-07-30
JP7116113B2 (ja) 2022-08-09
TWI755791B (zh) 2022-02-21
TW201639597A (zh) 2016-11-16
RU2017133273A3 (enExample) 2019-07-24
CN107405401B (zh) 2022-02-01
MX2017010773A (es) 2018-03-15
EP4279087A2 (en) 2023-11-22
CA2977767C (en) 2024-04-09
AU2021204217A1 (en) 2021-07-15
RU2714233C2 (ru) 2020-02-13
US10800846B2 (en) 2020-10-13
WO2016137985A1 (en) 2016-09-01
TW202110480A (zh) 2021-03-16
EP4279087A3 (en) 2024-01-31
IL278423B1 (en) 2023-12-01
RU2017133273A (ru) 2019-03-27
KR20170132171A (ko) 2017-12-01
MX393976B (es) 2025-03-21
CN107405401A (zh) 2017-11-28
IL278423A (enExample) 2020-12-31
SG10201810615VA (en) 2019-01-30
AU2021204211A1 (en) 2021-07-15
TWI748942B (zh) 2021-12-11
BR112017018234A2 (pt) 2018-04-17
JP6885869B2 (ja) 2021-06-16
US20200362040A1 (en) 2020-11-19
EP3262073A1 (en) 2018-01-03
IL254131B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
AU2016222928B2 (en) PD-1 / PD-L1 inhibitors for the treatment of cancer
US20190144545A1 (en) PD-1/PD-L1 Inhibitors for Cancer Treatment
RU2765997C2 (ru) Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
EP3856251B1 (en) Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
US20190216923A1 (en) Methods and combination therapy to treat cancer
RU2742312C1 (ru) Ингибиторы pd-1 / pd-l1 для лечения рака
HK40040793A (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
HK1242210A1 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
JP2025520098A (ja) Ｎｓｃｌｃを処置するためのバイオマーカーおよび方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired